Clinical Trial Update: Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating brostallicin or doxorubicin as first-line therapy for relapsed, refractory, or metastatic soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Small Intestine Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Brostallicin (brostallicin)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Ovarian Cancer, Sarcoma | Phase 2 | Status: UNKNOWN